DEA Issues ‘Final Order’ Rejecting Private Production Of Cannabis For FDA-Approved Research

[Editor's note: This post is excerpted from this week's forthcoming NORML weekly media advisory. To have NORML's media alerts and legislative advisories delivered straight to your in-box, sign up here. To watch NORML's weekly video summary of the week's top stories, click here.]

The United States Drug Enforcement Administration (DEA) has issued its final order rejecting a ruling from the agency’s own Administrative Law Judge finding that it would be ‘in the public interest’ to grant the University of Massachusetts a license to grow marijuana for federally regulated research.

The rejection preserves the monopoly held by National Institute on Drug Abuse (NIDA) on the supply of marijuana for Food and Drug Administration (FDA)-regulated research. In 2010, a spokesperson for the agency told the New York Times, “We generally do not fund research focused on the potential beneficial medical effects of marijuana.”

In 2007, after extensive hearings, DEA Judge Mary Ellen Bittner opined in favor of allowing a researcher at the University of Massachusetts at Amherst legal permission to cultivate marijuana for use in FDA-approved clinical trials.

She determined: “I conclude that granting Respondent’s application would not be inconsistent with the Single Convention, that there would be minimal risk of diversion of marijuana resulting from Respondent’s registration, that there is currently an inadequate supply of marijuana available for research purposes, that competition in the provision of marijuana for such purposes is inadequate, and that Respondent has complied with applicable laws and has never been convicted of any violation of any law pertaining to controlled substances. I therefore find that Respondent’s registration to cultivate marijuana would be in the public interest.”

DEA director Michele Leonhart initially set aside Judge Bittner’s ruling in 2009.

The agency’s ruling may be appealed in the First Circuit US Court of Appeals.

In July, the DEA denied a nine-year-old petition seeking to initiate hearings regarding the federal classification of cannabis as a schedule I controlled substance, stating in part, “[T]here are no adequate and well-controlled studies proving efficacy.”

Tremendous PBS Video Explains Why Medical Cannabis Works — And How Big Pharma Is Planning To Cash In On It

PBS is to be commended for producing this excellent video summarizing the science behind the use of cannabis as a medicine.

Want to know why cannabis is effective at treating multiple symptoms and conditions? Watch this video. Want to know how cannabinoids selectively target and kill cancer cells? Watch this video. Want to know how many patents Big Pharma has taken out on cannabis-derived synthetic drugs? Watch this video.

And then share it with your friends and family.

Watch the full episode. See more PBS NewsHour.

Obama Is Asked To Defend His Administration’s Opposition To Medical Cannabis — He Can’t

[Update! A slightly edited version of this commentary, entitled 'If Obama can't articulate his position on marijuana, why won't he reconsider it?', is is now online at The Hill.com's Congress blog here. Please review and leave your feedback for members of Congress and their staff here.]

Regardless of one’s opinion of President Obama as a political figure, it is hard to deny his skill as an eloquent orator. So it is notable, even newsworthy, when the Commander-in-Chief is publicly at a loss for words.

Such was the case yesterday at a Presidential Town hall in Cannon Falls, Minnesota when a flustered, tongue-tied Obama attempted in vain to explain why his administration continues to oppose efforts to allow for the legal use of cannabis as a doctor-recommended medicine.

Confused? Perhaps this transcript will help to better articulate the President’s position:

Audience member: “If you can’t legalize marijuana, why can’t we just legalize medical marijuana, to help the people that need it?”

Obama: “Well, you know, a lot of states are making decisions about medical marijuana. As a controlled substance, the issue then is, you know, is it being prescribed by a doctor, as opposed to, you know — well — – I’ll — I’ll — I’ll — I’ll leave it at that.”

And leave it at that he did.

It is curious that President Obama — someone who is use to speaking extemporaneously in public — could not articulate one single legitimate reason (nor could his former Press Secretary) why his administration believes in continuing the federal ban on marijuana, including the use of medical marijuana for ill patients. Obama’s failure to communicate becomes even more surprising when one considers that within just the past few weeks, high-profile members of the Obama administration have publicly put forward several alleged ‘justifications’ for why the federal government ought to be in the business of denying medical marijuana to sick people.

For instance, the White House’s 2011 National Drug Control Strategy, released in July, devoted an entire section to rebuffing the notion of cannabis’ use as a legitimate therapy, stating:

Marijuana and other drugs are addictive and unsafe, especially for use by young people. Unfortunately, efforts to “medicalize” marijuana have widened the public acceptance and availability of the drug.

There is no substitute for the scientific approval process employed by the FDA. For a drug to be made available to the public as medicine, the FDA requires rigorous research followed by tests for safety and efficacy. Only then can a substance be classified as medicine and prescribed by qualified health care professionals to patients.

In the wake of state and local laws that permit distribution of “medical” marijuana, dozens of localities have been left to grapple with poorly written laws that bypass the FDA process and allow marijuana to be used as a so-called medicine. … Outside the context of federally approved research, the use and distribution of marijuana is prohibited in the United States.

In addition, less than one-month ago, Obama’s hand-picked DEA Administrator Michele Leonhart formally denied a nine-year-old petition calling on the agency to initiate hearings to reassess the present classification of marijuana as a schedule I controlled substance without any ‘accepted medical use in treatment.’ Leonhart’s justification, as stated in in the July 8, 2011 edition of the Federal Register:

[Cannabis possesses] a high potential for abuse; … no currently accepted medical use in treatment in the United States; … [and] lacks accepted safety for use under medical supervision. … [T]here are no adequate and well-controlled studies proving its efficacy; the drug is not accepted by qualified experts. … At this time, the known risks of marijuana use have not been shown to be outweighed by specific benefits in well-controlled clinical trials that scientifically evaluate safety and efficacy.

So if the Obama administration is willing to make such allegations in writing, then why is the President afraid to own up to and repeat these claims in public? Likely because he, like a majority of Americans, are aware that there isn’t a shred of scientific support for the administration’s ‘Flat Earth’ position.

So if the President of the United States can’t publicly articulate why we continue to arrest over one-half million Americans each year for possessing marijuana, then why are we as a nation continuing to engage in this destructive and illogical policy?

NORML Women’s Alliance to Hold First Major Fundraising Weekend Dec 17-19 at KushCon II

NORML women will be descending upon Denver, Colorado next week to hold their first major fundraising event at KushCon II’s three-day lifestyle convention.  From Friday, December 17 to Sunday, December 19 the Colorado Convention Center will be buzzing with thousands of medical marijuana experts and enthusiasts in the largest cannabis lifestyle convention of the year, and the NORML Women’s Alliance (NWA) will play a prominent role.

Hydrobotanical Engineering, LLC, the company that owns the GrowBots franchise, has generously donated one of their major products, the GrowBot Garage to the NORML Women’s Alliance to be raffled at KushCon II.  Tickets will be sold throughout the weekend at the NORML Women’s Alliance booth inside the Denver  Convention Center.  If you are in town for KushCon II make sure to stop by the NORML Women’s Alliance booth to show your support and buy your raffle ticket (only $20 a ticket).

Several women of the Alliance’s newly formed steering committee will be in attendance, including Cheryl Shuman, Director of Public Relations and Media for Kush Magazine, KushCon and DailyBuds.com. Other NORML women who will be speaking and performing throughout the event include Nashville singer Greta Gaines, New Jersey NORML head Anne Davis, Esq, Colorado NORML’s Georgia Edson and NWA director Sabrina Fendrick.

The NORML Women’s Alliance fundraising weekend begins with a business-to-business networking event sponsored by the Medical Marijuana Business Alliance and KUSH Magazine on Thursday, December 16^th where the elite of the cannabis industry will gather to celebrate the movement and organize product and service giveaways expected to raise thousands of dollars.  For more information on the NWA’s involvement with KushCon II, please contact Cheryl Shuman at cheryl@dailybuds.com, 818.223.8011 or 818.835.7131.

The NORML Women’s Alliance is a nonpartisan coalition of prominent, educated, successful, geographically diverse, professional women who believe that cannabis prohibition is a self-destructive and hypocritical policy that undermines the American family, sends a mixed and false message to our young people, and destroys the cherished principles of personal liberty.

Obama’s DEA Nominee Pledges To Ignore Administration’s Medical Marijuana Policy

It was a little over a year ago when the United States Department of Justice announced that it would back away from pursuing cases against medical marijuana patients and providers who are acting in accordance with state and local laws.

“As a general matter, pursuit of [federal law enforcement] priorities should not focus federal resources … on individuals whose actions are in clear and unambiguous compliance with existing state laws providing for the medical use of marijuana,” The DOJ announced on October 19, 2009. “For example, prosecution of individuals with cancer or other serious illnesses who use marijuana as part of a recommended treatment regimen consistent with applicable state law, or those caregivers in clear and unambiguous compliance with existing state law who provide such individuals with marijuana, is unlikely to be an efficient use of limited federal resources.”

Apparently Michelle Leonhart, President Obama’s nominee to direct the United States Drug Enforcement Administration, didn’t get the memo.

Speaking yesterday before the Senate Judiciary Committee, on day one of her Senate confirmation process, Leonhart pledged to ignore the administration’s formal medical marijuana guidelines.

Michele Leonhart one step closer to officially heading up the DEA
via The Daily Caller

[excerpt] Acting director Michele Leonhart is that much closer to officially heading up the Drug Enforcement Agency after successfully navigating a hearing with the Senate Judiciary Committee on Wednesday.

If confirmed to the position she’s already held for three years, Leonhart said she would expand the DEA’s anti-cartel operations in Mexico and continue to enforce federal drug laws in states where medical marijuana is legal.

… Perhaps due to the failure of Prop 19 in California (and despite the passage of medical marijuana in Arizona), Kohl, along with Democratic Sens. Sheldon Whitehouse of Rhode Island and Al Franken of Minnesota, made no mention of medical marijuana. Republican Sen. Jeff Sessions of Alabama, however, made it his prime focus.

“I’m a big fan of the DEA,” said Sessions, before asking Leonhart point blank if she would fight medical marijuana legalization.

“I have seen what marijuana use has done to young people, I have seen the abuse, I have seen what it’s done to families. It’s bad,” Leonhart said. “If confirmed as administrator, we would continue to enforce the federal drug laws.”

“These legalization efforts sound good to people,” Sessions quipped. “They say, ‘We could just end the problem of drugs if we could just make it legal.’ But any country that’s tried that, Alaska and other places have tried it, have failed. It does not work,” Sessions said.

“We need people who are willing to say that. Are you willing to say that?” Sessions asked Leonhart.

“Yes, I’ve said that, senator. You’re absolutely correct [about] the social costs from drug abuse, especially from marijuana,” Leonhart said. “Legalizers say it will help the Mexican cartel situation; it won’t. It will allow states to balance budgets; it won’t. No one is looking [at] the social costs of legalizing drugs.”

It is shocking to learn that not a single Senator who attended the hearing, in particular Democrat Sen. Sheldon Whitehouse from Rhode Island, had the courage to demand that Ms. Leonhart respect the laws of the 15 states that have legalized the use of marijuana as a medicine. In the case of Sen. Whitehouse, his own state is now in the process of licensing state-certified marijuana providers and distributors; yet he appears to have no problem with the idea of appointing a federal official who declares her intention to put his own constituents in federal prison.

It gets even more disturbing. In the days leading up to Wednesday’s initial confirmation hearing, a coalition of advocacy groups — including NORML, Americans for Safe Access, and others called on members of the Senate Judiciary to ask Ms. Leonhart tough questions regarding her public record, one that is incompatible with state laws, public opinion, and with the policies of this administration. Yet not a single Senator did so.

There is a growing divide between state and federal law concerning the use of marijuana for medical purposes, and it would only take members of the Senate — or Ms. Leonhart for that matter — a cursory scan of today’s google headlines to see it:

Prop 203 Passes: Medical Marijuana to Be Legal in Arizona
via CBS News

New Mexico approves six new medical marijuana producers
via The New Mexico Independent

Maine couple cleared to open marijuana clinic
via The Associated Press

DC revises medical marijuana regulations
via Comcast

As we’ve written before, as Interim DEA director, Ms. Leonhart has overseen dozens of federal raids on medical marijuana providers, producers, and laboratory facilities that engage in the testing of cannabis potency and quality. Yesterday Ms. Leonhart pledged to continue these actions — actions that violate this administration’s own written policies, and more importantly, actions that target the civilians of fifteen states and the District of Columbia. These people are the constituents of 30 percent of the U.S. Senate; yet not even one of these elected officials appears willing to speak up for them. That is disgraceful.

Want to write or call your Senator about Ms. Leonhart’s nomination process? You can still do so here and here.